DOI 10.1080/1750743x.2026.2705727
Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.
Аннотация
INTRODUCTION
This review summarizes recent findings from meta-analyses on lupus nephritis (LN) therapies to promote precision medicine and address the challenge of fragmented evidence.
METHODS
A literature search identified 34 relevant meta-analyses published between January 2021 and March 2025.
RESULTS
Key findings include: Biological agents, particularly Belimumab and Obinutuzumab, significantly improve complete renal remission (CR) and reduce the risk of end-stage renal disease, breaking through traditional therapeutic bottlenecks. However, rituximab, while effective, carries a higher infection risk (SUCRA = 74.98%). The combination of tacrolimus and mycophenolate mofetil doubled the CR rate compared to monotherapy (OR = 2.85), but requires monitoring for creatinine elevation. Voclosporin use is limited by a high infection risk. The combination of Tripterygium glycosides and Western medicine increased the CR rate by 61% (RR = 1.61), while Astragalus-containing Chinese herbal medicine significantly reduced proteinuria (SMD = 0.51), highlighting the value of traditional Chinese medicine in enhancing efficacy and reducing toxicity. Glucocorticoid therapy presents a critical trade-off: an initial dose >60 mg/day improves CR to 34.6% but elevates severe infection and mortality rates to 12.1% and 2.7%, respectively, underscoring the urgent need for dose precision. In diagnostics, urinary TWEAK demonstrates high specificity. Mesenchymal stem cell therapy achieved a 33.7% remission rate.
CONCLUSION
In conclusion, this review provides a comprehensive overview of recent research on LN treatment, offering evidence-based support for clinical decision-making and points out directions for future research.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.